Although Helicobacter pylori infection is both a common and a serious bacterial infection,
antimicrobial therapies have rarely been optimized, are prescribed empirically, and provide …

Data are available such that choice of Helicobacter pylori therapy for an individual patient
can be reliably predicted. Here, treatment success is defined as a cure rate of 90% or …

Triple therapy, consisting of two antibiotics, clarithomycin and amoxicillin or metronidazole in
combination with a proton pump inhibitor (PPI) has become the first-line option for infection …

Helicobacter pylori infection causes progressive damage to gastric mucosa and results in
serious disease such as peptic ulcer disease, MALT lymphoma, or gastric adenocarcinoma …

Helicobacter pylori infection is the main cause of gastritis, gastroduodenal ulcer and gastric
cancer and should be considered as a major public health issue. According to several …

Helicobacter pylori is one of the most common human pathogens and it has been estimated
that about 50% of the world's population is currently infected. The present consensus is that …

Helicobacter pylori (H. pylori) infection is highly associated with the occurrence of
gastrointestinal diseases, including gastric inflammation, peptic ulcer, gastric cancer, and …

Helicobacter pylori infects approximately half the world's population and is especially
prevalent in the developing world. H. pylori is an important cause of global ill health due to …

The currently recommended first-line treatments are effective and well tolerated. In areas
with high antimicrobial resistance rates, new antibiotic combinations and modifications in the …

Helicobacter pylori (H. Pylori) is a leading cause of gastroduodenal disease, including
gastric cancer. H. pylori eradication therapies and their efficacy are summarized. A number …